Home
Clinical Trials
Molecular Studies and Clinica...

Molecular Studies and Clinical Correlations in Human Prostatic Disease

Last Updated: 2025-08-27

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

ACTIVE_NOT_RECRUITING

Total Enrollment

5290 participants

Study Classification

OBSERVATIONAL

Study Start Date

1990-04-30

Study Completion Date

2026-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The Genitourinary Oncology/Urology Services at Memorial Sloan-Kettering Cancer Center (MSKCC) participates in research for the control, treatment, and cure of cancer. The purpose of this study is to collect normal and cancerous tissues, in addition to blood, and other body fluid samples from men with prostate cancer or prostatic disease. These samples may be stored for future use or used immediately by researchers who study prostate cancer and try to find better ways to diagnose, prevent, and treat it. We will look for genetic changes and protein markers on these cells. We hope to learn more about what makes some people get prostate cancer, why some cancers are more aggressive than others, and why some cancers respond to or resist different treatments. We may also try to grow the tumor cells in the lab. We may find a new treatment for prostate cancer based on this research.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Prospective CiRculating prOstate Cancer Predictors in HighEr Risk mCRPC studY

NCT02269982

Prostate Cancer

COMPLETED

Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC)

NCT02380274

Prostate Cancer Castration-resistant Prostate Cancer Metastatic Prostate Cancer

COMPLETED

Platform Study for Prostate Researching Translational Endpoints Correlated to Response to Inform Use of Novel Combinations

NCT03835533

Metastatic Castration-resistant Prostate Cancer

COMPLETED PHASE1

Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer

NCT06145633

Castration-Resistant Prostate Carcinoma Metastatic Prostate Adenocarcinoma Stage IVB Prostate Cancer AJCC v8

RECRUITING PHASE2

Fractionated and Multiple Dose 225Ac-J591 for Progressive mCRPC

NCT04506567

Prostate Cancer

ACTIVE_NOT_RECRUITING PHASE1/PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The therapeutics program for advanced prostate cancer is based on the hypothesis that the factors contributing to and associated with progression change as the disease evolves. To categorize these changes we now consider the disease as a series of states. 1 The states represent points where an intervention might be considered to prevent cancer from developing, to eliminate established disease, or to delay progression. The states also represent clinically significant milestones that can be used to assess treatment effects.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Prostate Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Men with prostate conditions representing the following disease states:

* No Cancer Diagnosis
* Clinically Localized Disease
* Rising PSA
* Clinical Metastases: Noncastrate
* Clinical Metastases: Castrate (Testosterone ≤ 50 ng/ml)
* Signed informed consent